Thus, we suggest that during trastuzumab treatment in cancer patients, trastuzumab stimulates IFN-γ production, which turns PD-L1-negative “hot” tumors into PD-L1+ “cold” tumors, evading immune attacks mediated by T and NK cells. This evidence concerns the gene IFNG and cancer.